Literature DB >> 6692252

Malignant mesothelioma. The University of Minnesota experience.

N J Vogelzang, S M Schultz, A M Iannucci, B J Kennedy.   

Abstract

Between 1950 and 1981, 31 patients with mesothelioma were treated at the University of Minnesota. An average of 0.2 to 0.6 patients were seen per year between 1950 and 1970, and since 1970 there has been an average of 1.4 to 2.4 patients per year. Twenty-seven of the 28 patients with malignant mesothelioma are known or presumed dead. Mesotheliomas occurred in all areas of Minnesota, and 28.6% of the patients had a definite history of asbestos exposure. This was also a probable cause of the disease in an additional 25% of patients. The clinical findings and course of the disease were similar to other series. The median survival of all patients was eight months. Doxorubicin-treated patients survived a median of 16 months (range, 2-36 months). Malignant mesothelioma is being increasingly recognized in Minnesota and has a grim prognosis in spite of doxorubicin therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6692252     DOI: 10.1002/1097-0142(19840201)53:3<377::aid-cncr2820530302>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.

Authors:  N J Vogelzang; M Goutsou; J M Corson; Y Suzuki; S Graziano; J Aisner; M R Cooper; K M Coughlin; M R Green
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and causes of death.

Authors:  J Ribak; R Lilis; Y Suzuki; L Penner; I J Selikoff
Journal:  Br J Ind Med       Date:  1988-03

3.  Primary malignant mesothelioma of the pericardium.

Authors:  A S Kumar
Journal:  Tex Heart Inst J       Date:  1994

4.  Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.

Authors:  Robert Ryan Meyerhoff; Chi-Fu Jeffrey Yang; Paul J Speicher; Brian C Gulack; Matthew G Hartwig; Thomas A D'Amico; David H Harpole; Mark F Berry
Journal:  J Surg Res       Date:  2015-01-29       Impact factor: 2.192

5.  Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival.

Authors:  A Baldi; A M Groeger; V Esposito; R Cassandro; G Tonini; T Battista; M P Di Marino; B Vincenzi; M Santini; A Angelini; R Rossiello; F Baldi; M G Paggi
Journal:  Thorax       Date:  2002-04       Impact factor: 9.139

Review 6.  Cerebral metastases in pleural mesothelioma: case report and review of the literature.

Authors:  M Wroński; M Burt
Journal:  J Neurooncol       Date:  1993-07       Impact factor: 4.130

7.  Malignant mesothelioma: attributable risk of asbestos exposure.

Authors:  R Spirtas; E F Heineman; L Bernstein; G W Beebe; R J Keehn; A Stark; B L Harlow; J Benichou
Journal:  Occup Environ Med       Date:  1994-12       Impact factor: 4.402

8.  Survival of asbestos insulation workers with mesothelioma.

Authors:  J Ribak; I J Selikoff
Journal:  Br J Ind Med       Date:  1992-10

9.  Presentation of malignant pleural mesothelioma with cerebral metastases.

Authors:  W M McNaughton; M E Broughton; G C Toner; M A Schwarz
Journal:  J R Soc Med       Date:  1990-07       Impact factor: 18.000

10.  Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.

Authors:  Elly Marcq; Jorrit De Waele; Jonas Van Audenaerde; Eva Lion; Eva Santermans; Niel Hens; Patrick Pauwels; Jan P van Meerbeeck; Evelien L J Smits
Journal:  Oncotarget       Date:  2017-09-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.